FDA Class II Recall: SV Labs Prescott Corporation's Sunscreen Fails Microbial Count, Raising cGMP Compliance Concerns
SV Labs Prescott Corporation initiated a Class II recall of Aloe Up Sport Performance Sunscreen Lotion SPF 30 due to cGMP deviations and failed microbial count testing. This event underscores critical supply chain risks for procurement and regulatory teams, highlighting the imperative for stringent quality oversight in contract manufacturing and robust supplier qualification processes to safeguard brand integrity and consumer safety.
FDA Identifies Critical cGMP Deviations in SV Labs Prescott Sunscreen Production
SV Labs Prescott Corporation has initiated a Class II recall, D-0022-2026, for 11,386 tubes of Aloe Up Sport Performance Sunscreen Lotion SPF 30, 1 FL OZ (30 mL), specifically Lot#: 25196 with an expiration date of February 16, 2026. This voluntary, firm-initiated action, commencing on September 25, 2025, stems from significant current Good Manufacturing Practice (cGMP) deviations. The primary failure identified was the release and distribution of product that did not meet total aerobic microbial count testing requirements. For procurement directors and regulatory affairs heads, this incident at SV Labs Prescott Corporation's facility in Prescott, Wisconsin, signals a fundamental breakdown in quality control processes. The failure to meet microbial specifications for an over-the-counter (OTC) drug product like sunscreen poses direct risks to consumer health and safety, potentially leading to skin irritation or infection, especially for individuals with compromised immune systems. This necessitates an immediate review of quality assurance protocols for any products sourced from or manufactured by SV Labs Prescott Corporation, or similar contract manufacturing organizations (CMOs) in the United States. Business development executives must recognize that such cGMP non-compliance can severely impact brand reputation and market access, demanding rigorous due diligence on manufacturing partners.
SV Labs Prescott Corporation's Operational Footprint and Product Scope Under Scrutiny
The facility at 1115 Dexter St N, Prescott, WI, United States, operated by SV Labs Prescott Corporation, is the manufacturing site implicated in this recall. While the specific product involved is Aloe Up Sport Performance Sunscreen Lotion SPF 30, manufactured for ALOE UP of Eden Prairie, Minnesota, the cGMP deviations related to microbial control suggest potential systemic issues that could affect other products manufactured at this site. For supply chain VPs, understanding the full product portfolio and market reach of SV Labs Prescott Corporation is crucial. Any other drug products, cosmetics, or personal care items produced by this facility could be subject to similar quality risks, necessitating a comprehensive risk assessment across all product lines. Procurement teams must ascertain if their organizations have any direct or indirect sourcing relationships with SV Labs Prescott Corporation, or if their brand partners utilize this CMO. The nationwide distribution pattern of the recalled sunscreen further amplifies the potential impact, indicating a broad market exposure for any quality lapses originating from this Wisconsin-based facility. This event underscores the need for robust supplier qualification and ongoing monitoring, regardless of the domestic location of the manufacturing site.
Supply Chain Exposure: Direct Impact on ALOE UP and Downstream Retailers
The recall directly impacts ALOE UP, the brand for whom the Aloe Up Sport Performance Sunscreen Lotion SPF 30 was manufactured. As the marketing authorization holder, ALOE UP bears the primary responsibility for the product's quality and safety, facing significant reputational damage and financial implications from retrieving 11,386 tubes distributed across the USA. For other brands relying on contract manufacturers, this case serves as a critical reminder that the ultimate burden of product quality and regulatory compliance rests with the brand owner. Supply chain VPs must ensure their vendor management programs incorporate continuous quality performance monitoring and clear accountability frameworks with CMOs. Retailers nationwide that stocked the affected Lot#: 25196 of Aloe Up Sport Performance Sunscreen Lotion SPF 30 must now manage the logistical complexities of inventory removal, customer notifications, and processing returns. This incurs direct operational costs, potential stock-outs, and, more importantly, can erode consumer trust in both the ALOE UP brand and the retail outlets carrying the product. Business development executives should evaluate the resilience of their brand partnerships against such quality failures, emphasizing the need for diversification of manufacturing sources and stringent quality clauses in all contracts.
Broader Regulatory Landscape: Heightened Scrutiny on Microbial Control in OTC Drugs
This Class II recall by SV Labs Prescott Corporation, driven by cGMP deviations and failed total aerobic microbial count testing, highlights the FDA's persistent focus on microbial control within drug product manufacturing, including over-the-counter formulations like sunscreen. The Class II classification indicates that exposure to the product could cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote, yet the risk is significant enough to warrant a nationwide recall. This incident aligns with a broader trend of regulatory scrutiny on microbial assurance, as evidenced by recent parallel events such as the FDA Class II Recall concerning Essential Wellness Pharma's Progesterone Injection for sterility assurance failures. For regulatory affairs and quality assurance teams, this reinforces the absolute necessity of robust environmental monitoring programs, stringent water system controls, and comprehensive raw material testing. Any manufacturer of drug products, particularly those producing semi-solid or liquid formulations, must proactively review and fortify their microbial control strategies. Non-compliance in this critical area can lead to costly product recalls, market withdrawals, and severe regulatory enforcement actions, directly impacting a company's financial performance and market standing.
Remediation Pathways and Future Compliance Outlook for SV Labs Prescott
The voluntary, firm-initiated nature of this recall by SV Labs Prescott Corporation indicates an acknowledgment of the cGMP deviation and an initial step towards corrective action. However, with the recall status currently 'Ongoing,' the full scope of remediation and its effectiveness remain under evaluation. For procurement and regulatory teams, immediate engagement with SV Labs Prescott Corporation is critical to understand the root cause analysis, the extent of the cGMP breakdown, and the comprehensive corrective and preventive actions (CAPA) plan being implemented. This includes assessing whether the microbial contamination was an isolated incident or indicative of systemic quality control deficiencies across the facility. Business development executives must consider the long-term implications for SV Labs Prescott Corporation as a reliable manufacturing partner. Insufficient or delayed remediation could lead to further FDA enforcement, including potential Warning Letters, import alerts (if applicable to other products), or even facility shutdowns, which would severely disrupt supply chains. Proactive contingency planning, including identifying and qualifying alternative manufacturing partners, is paramount to mitigate future supply risks associated with this ongoing regulatory event and ensure business continuity.